A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT ID: NCT03573908

Last Updated: 2020-12-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

614 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-20

Study Completion Date

2019-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome Characterized by Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Linaclotide 290 µg

Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.

Group Type EXPERIMENTAL

Linaclotide

Intervention Type DRUG

Oral capsule

Placebo

Intervention Type DRUG

Matching placebo oral capsule

Placebo

Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.

Group Type PLACEBO_COMPARATOR

Linaclotide

Intervention Type DRUG

Oral capsule

Placebo

Intervention Type DRUG

Matching placebo oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linaclotide

Oral capsule

Intervention Type DRUG

Placebo

Matching placebo oral capsule

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Linzess

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has no clinically significant findings on a physical examination and clinical laboratory tests
* Female patients of childbearing potential must agree to use one of the following methods of birth control:

1. Hormonal contraception
2. Double-barrier birth control
3. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy
* Patient meets protocol criteria for diagnosis of IBS-C
* Patient demonstrates continued IBS-C symptoms through Pretreatment Period
* Patient maintains a minimum level of compliance with daily diary

Exclusion Criteria

* Patient has history of loose or watery stools
* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain
* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan Sales, LLC

INDUSTRY

Sponsor Role collaborator

Ironwood Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wilmin Bartolini, PhD

Role: STUDY_CHAIR

Ironwood Pharmaceuticals, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Research Associates

Huntsville, Alabama, United States

Site Status

Elite Clinical Studies

Phoenix, Arizona, United States

Site Status

Adobe Clinical Research, LLC

Tucson, Arizona, United States

Site Status

Arkansas Gastroenterology

North Little Rock, Arkansas, United States

Site Status

GW Research, Inc.

Chula Vista, California, United States

Site Status

Kindred Medical Institute for Clinical Trials, LLC

Corona, California, United States

Site Status

Diagnamics, Inc.

Encinitas, California, United States

Site Status

MD Studies, Inc.

Fountain Valley, California, United States

Site Status

Paragon Rx Clinical, Inc. - Garden Grove

Garden Grove, California, United States

Site Status

Grossmont Center For Clinical Research

La Mesa, California, United States

Site Status

Facey Medical Foundation

Mission Hills, California, United States

Site Status

Providence Clinical Research

North Hollywood, California, United States

Site Status

Precision Research Institute

San Diego, California, United States

Site Status

Paragon Rx Clinical, Inc.- Santa Ana

Santa Ana, California, United States

Site Status

Millennium Clinical Trials

Thousand Oaks, California, United States

Site Status

St. Joseph Heritage Healthcare

Yorba Linda, California, United States

Site Status

Connecticut Clinical Research Institute

Bristol, Connecticut, United States

Site Status

Chase Medical Research, LLC

Waterbury, Connecticut, United States

Site Status

Clinical Research of South Florida

Coral Gables, Florida, United States

Site Status

Avail Clinical Research, LLC

DeLand, Florida, United States

Site Status

Palmetto Research, LLC

Hialeah, Florida, United States

Site Status

Nature Coast Clinical Research, LLC

Inverness, Florida, United States

Site Status

The Chappel Group Research

Kissimmee, Florida, United States

Site Status

Jesscan Medical Research

Miami, Florida, United States

Site Status

Well Pharma Medical Research Corporation

Miami, Florida, United States

Site Status

New Horizon Research Center

Miami, Florida, United States

Site Status

San Marcus Research Clinic, Inc.

Miami Lakes, Florida, United States

Site Status

Ocean Blue Medical Research Center, Inc.

Miami Springs, Florida, United States

Site Status

Ormond Medical Arts Pharmaceutical Research Center

Ormond Beach, Florida, United States

Site Status

Precision Clinical Research

Sunrise, Florida, United States

Site Status

Meridien Research - Tampa

Tampa, Florida, United States

Site Status

Palm Beach Research Center

West Palm Beach, Florida, United States

Site Status

Research Institute of Central Florida, LLC

Winter Park, Florida, United States

Site Status

Mount Vernon Clinical Research, LLC

Sandy Springs, Georgia, United States

Site Status

Clinical Trials Management, LLC

Metairie, Louisiana, United States

Site Status

Delta Research Partners, LLC

Monroe, Louisiana, United States

Site Status

Louisiana Research Center, LLC

Shreveport, Louisiana, United States

Site Status

Alan A. Rosen, MD, PA

Baltimore, Maryland, United States

Site Status

Meritus Center For Clinical Research

Hagerstown, Maryland, United States

Site Status

Boston Clinical Trials, Inc.

Boston, Massachusetts, United States

Site Status

MedVadis Research Corporation

Watertown, Massachusetts, United States

Site Status

Gastroenterology Associates of West Michigan

Wyoming, Michigan, United States

Site Status

Gastrointestinal Associates PA

Flowood, Mississippi, United States

Site Status

St. Louis Center For Clinical Research

St Louis, Missouri, United States

Site Status

Bozeman Health Deaconess Hospital

Bozeman, Montana, United States

Site Status

Clinical Research of South Nevada

Las Vegas, Nevada, United States

Site Status

Healthwise Medical Associates

Brooklyn, New York, United States

Site Status

Long Island Gastrointestinal Research Group, LLP

Great Neck, New York, United States

Site Status

Carolina Digestive Health Associates

Charlotte, North Carolina, United States

Site Status

Carolina Digestive Health Associates

Concord, North Carolina, United States

Site Status

Cumberland Research Associates

Fayetteville, North Carolina, United States

Site Status

Peters Medical Research, LLC

High Point, North Carolina, United States

Site Status

Wake Research Associates, LLC

Raleigh, North Carolina, United States

Site Status

PMG Research of Wilmington

Wilmington, North Carolina, United States

Site Status

Clinical Trials of America - North Carolina, LLC

Winston-Salem, North Carolina, United States

Site Status

Lyndhurst Clinical Research

Winston-Salem, North Carolina, United States

Site Status

PMG Research of Winston-Salem

Winston-Salem, North Carolina, United States

Site Status

Lillestol Research

Fargo, North Dakota, United States

Site Status

Hightop Medical Research Center

Cincinnati, Ohio, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

Remington Davis, Inc.

Columbus, Ohio, United States

Site Status

Dayton Gastroenterology, Inc.

Dayton, Ohio, United States

Site Status

Hometown Urgent Care and Research

Dayton, Ohio, United States

Site Status

Great Lakes Gastroenterology Research, LLC

Mentor, Ohio, United States

Site Status

IPS Research Company

Oklahoma City, Oklahoma, United States

Site Status

Partners In Clinical Research

Cumberland, Rhode Island, United States

Site Status

Mountain View Clinical Research, Inc.

Greer, South Carolina, United States

Site Status

Meridian Clinical Research

Dakota Dunes, South Dakota, United States

Site Status

ClinSearch, LLC

Chattanooga, Tennessee, United States

Site Status

New Phase Research & Development

Knoxville, Tennessee, United States

Site Status

MW Clinical Research Center

Beaumont, Texas, United States

Site Status

Southwest Clinical Trials

Houston, Texas, United States

Site Status

Southwest Clinical Trials

Houston, Texas, United States

Site Status

Quality Research, Inc.

San Antonio, Texas, United States

Site Status

Diagnostics Research Group

San Antonio, Texas, United States

Site Status

Stone Oak, LLC dba Discovery Clinical Trials

San Antonio, Texas, United States

Site Status

Advanced Research Institute

Ogden, Utah, United States

Site Status

New River Valley Research Institute

Christiansburg, Virginia, United States

Site Status

Blue Ridge Medical Research

Lynchburg, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Brenner DM, Lacy BE, Ford AC, Bartolini W, Wu J, Shea EP, Bochenek W, Boinpally R, Almansa C. Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials. Am J Gastroenterol. 2023 May 1;118(5):872-879. doi: 10.14309/ajg.0000000000002064. Epub 2022 Oct 12.

Reference Type DERIVED
PMID: 36227782 (View on PubMed)

Chang L, Lacy BE, Moshiree B, Kassebaum A, Abel JL, Hanlon J, Bartolini W, Boinpally R, Bochenek W, Fox SM, Mallick M, Tripp K, Omniewski N, Shea E, Borgstein N. Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System. Am J Gastroenterol. 2021 Sep 1;116(9):1929-1937. doi: 10.14309/ajg.0000000000001334.

Reference Type DERIVED
PMID: 34465695 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MCP-103-312

Identifier Type: -

Identifier Source: org_study_id